First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses.

@article{Ottenhoff2010FirstIH,
  title={First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses.},
  author={Tom H. M. Ottenhoff and T Mark Doherty and Jaap T. van Dissel and Peter Bang and Karen Lingnau and Ingrid Kromann and Peter Andersen},
  journal={Human vaccines},
  year={2010},
  volume={6 12},
  pages={
          1007-15
        }
}
Tuberculosis (TB) remains a major killer worldwide. The only available TB-vaccine, the nearly century-old Mycobacterium bovis BCG, has had only a limited effect on TB incidence. Therefore, developing new TB vaccines is a key priority, and the first new generation TB vaccines are now being tested in clinical trials. Here we describe the development and first testing in humans of a novel, wholly synthetic TB subunit vaccine. This vaccine has proven safe and highly immunogenic in all species in… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Current status of new tuberculosis vaccine in children.

  • Human vaccines & immunotherapeutics
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Strategies for designing novel tuberculosis vaccines

  • Biology Bulletin Reviews
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND